A Randomized,Parallel Group,Open Label,Active Controlled Clinical Study To Evaluate The Safety And Efficacy Of A Topical Unani Formulation Compared With Clobetasol Propionate In The Management Of Nar Farsi(Eczema)
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Change in EASI Score from baseline to 8 weeks of treatment
研究概览
简要总结
Eczema (Nar Farsi) is a prevalent and distressing skin condition affecting individuals of all ages, with rising global incidence. It significantly impacts quality of life through physical discomfort, psychological stress, and financial burden. Conventional treatments, especially topical corticosteroids, though effective in the short term, pose risks with long-term use and may lead to treatment failure or adverse effects. Dimad, a traditional Unani formulation, is historically used for managing inflammatory skin conditions like eczema. Given the growing need for safer, effective alternatives, this study aims to evaluate the safety and efficacy of Dimad compared to Clobetasol Propionate in managing Nar Farsi (Eczema).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •The following participants will be included in the study: 1)Participants of any sex aged between 18 to 60 years 2)Participants having the following symptoms: Erythema Scaling Excoriation Hyperpigmentation Burning sensation Itching.
排除标准
- •The following participants will be excluded: 1)Participants aged less than 18 years or more than 60 years 2)Participants on concomitant therapy.
- •Known case of Diabetes mellitus.
- •Pregnant or Lactating Women.
- •Significant Pulmonary,Cardiovascular,Hepato-renal Dysfunction.
- •Known cases of Immunocompromised states (HIV,AIDS, etc.),malignancies.
结局指标
主要结局
Change in EASI Score from baseline to 8 weeks of treatment
时间窗: at baseline,2,4,6,8 week
次要结局
- 1)Change in CDSQ score from baseline to 8 week.(2)systemic safety assessment.)
研究者
DR ANSARI HINA KAUSAR MOHAMMAD JALIL
National Research Institute Of Unani Medicine For Skin Disorders(NRIUMSD)